Role of the Tristetraprolin (Zinc Finger Protein 36 Homolog) Gene in Cancer

Crit Rev Eukaryot Gene Expr. 2018;28(3):217-221. doi: 10.1615/CritRevEukaryotGeneExpr.2018021188.

Abstract

Cancer is a complicated transformational progression that fiercely changes the appearance of cell physiology as well as cells' relations with adjacent tissues. Developing an oncogenic characteristic requires a wide range of modifications in a gene expression at a cellular level. This can be achieved by activation or suppression of the gene regulation pathway in a cell. Tristetraprolin (TTP or ZFP36) associated with the initiation and development of tumors are regulated at the level of mRNA decay, frequently through the activity of AU-rich mRNA-destabilizing elements (AREs) located in their 3'-untranslated regions. TTP is an attractive target for therapeutic use and diagnostic tools due to its characteristic appearance in cancer tissue alone. Thus, the illumination of TTP in diverse types of cancer might deliver additional effective remedies in the coming era for cancer patients. The objective of this review is to familiarize the reader with the TTP proteins, focus on efficient properties that endow them with their effective oncogenic potential, describe their physiological role in cancer cells, and review the unique properties of TT, and of TTP-driven cancer.

Publication types

  • Review

MeSH terms

  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Neoplasms / genetics*
  • RNA Stability / genetics
  • RNA, Messenger / genetics
  • Tristetraprolin / genetics*

Substances

  • RNA, Messenger
  • Tristetraprolin
  • ZFP36 protein, human